Aspire Biopharma Holdings (ASBP) Free Cash Flow (2021 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Free Cash Flow came in at -$3.0 million in Q1 2026, down 73.48% year-on-year from -$11.5 million in Q1 2025, and down 227.48% on a QoQ basis from -$927841.0 in Q4 2025.
Aspire Biopharma Holdings (ASBP) Free Cash Flow (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has 6 years of Free Cash Flow data on file, last reported at -$3.0 million in Q1 2026.
- On a quarterly basis, Free Cash Flow fell 73.48% year-over-year to -$3.0 million in Q1 2026; TTM through Mar 2026 was -$6.2 million, a 240.53% decrease from a year earlier, with the FY2025 full-year figure at -$4.9 million, down 1214.54% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$3.0 million, down from -$927841.0 in the prior quarter.
- Over the last five years, Free Cash Flow for ASBP reached as high as $479569.0 in Q4 2024 and fell as low as -$3.0 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$605240.5 across 5 years, with a median of -$189951.0 in 2023.
- Across the five-year window, Free Cash Flow surged 407.16% in 2024 and sank 1927.43% in 2025, its largest moves.
- Year by year, Free Cash Flow stood at -$35870.0 in 2022, then plunged by 335.26% to -$156128.0 in 2023, then jumped by 407.16% to $479569.0 in 2024, then tumbled by 293.47% to -$927841.0 in 2025, then plunged by 227.48% to -$3.0 million in 2026.
- Per Business Quant data, the three most recent Free Cash Flow figures were -$3.0 million in Q1 2026, -$927841.0 in Q4 2025, and -$1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.14 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.46 Bn | 37.46 Bn | - | -354.95 Mn |
| 10 | Aspire Biopharma Holdings | 1.10 Mn | -724,996.75 | 5,750.00 | -3.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.04 Mn |
| Mar 31, 2026 | -3.04 Mn |
| Dec 31, 2025 | -927,841.00 |
| Dec 31, 2025 | -927,841.00 |
| Sep 30, 2025 | -1.10 Mn |
| Sep 30, 2025 | -1.10 Mn |
| Jun 30, 2025 | -1.14 Mn |
| Jun 30, 2025 | -1.14 Mn |
| Mar 31, 2025 | -1.75 Mn |
| Mar 31, 2025 | -1.75 Mn |
| Dec 31, 2024 | 479,569.00 |
| Dec 31, 2024 | 479,569.00 |
| Sep 30, 2024 | -495,540.00 |
| Sep 30, 2024 | -495,540.00 |
| Jun 30, 2024 | -56,244.00 |
| Jun 30, 2024 | -56,244.00 |
| Mar 31, 2024 | -192,971.00 |
| Mar 31, 2024 | -192,971.00 |
| Dec 31, 2023 | -156,128.00 |
| Dec 31, 2023 | -156,128.00 |